Request for Covid-19 Impact Assessment of this Report

Healthcare

Global Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Region: Trend Forecast and Growth Opportunity

  • GRA4209040
  • 185 Pages
  • March 2021
  • Healthcare
Download Sample    Get Discount   
 
Global pharmaceutical manufacturing industry will reach $673.6 billion by 2027, growing by 12.5% annually over 2020-2027 driven by increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high investment in research and development, and increasing per capita healthcare expenditure amid the COVID-19 pandemic.

Highlighted with 85 tables and 96 figures, this 185-page report “Global Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global pharmaceutical manufacturing industry and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate/forecast from 2020 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Industry Structure

• Growth Drivers

• Restraints and Challenges

• Emerging Product Trends & Industry Opportunities

• Porter’s Fiver Forces

The trend and outlook of global industry is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global pharmaceutical manufacturing industry in every aspect of the classification from perspectives of Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Region.

Based on Formulation, the global industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.

• Tablets

• Capsules

• Injectable

• Sprays

• Suspensions

• Powders

• Other Formulations

Based on Route of Administration, the global industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.

• Oral Medicine

• Topical Medicine

• Parenteral Medicine

• Inhalations

• Other Routes of Administration

Based on Age Group, the global industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.

• Children & Adolescents

• Adults

• Geriatric

Based on Therapeutic Application, the global industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.

• Cardiovascular Diseases

• Pain

• Diabetes

• Cancer

• Respiratory Diseases

• Neurological Diseases

• Orthopedics

• Other Applications

Based on Drug Type, the global industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.

• Branded Prescription Drugs

• Generic Prescription Drugs

• OTC Drugs

Based on Distribution Channels, the global industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.

• Retail Channels

• Non-retail Channels

Based on Manufacturing Facility, the global industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.

• In-house Facility

• Outsourced Facility

Geographically, the following regions together with the listed national/local markets are fully investigated:

• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Turkey, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)

• North America (U.S., Canada, and Mexico)

• South America (Brazil, Chile, Argentina, Rest of South America)

• MEA (UAE, Saudi Arabia, South Africa)

For each aforementioned region and country, detailed analysis and data for annual production value are available for 2017-2027. The breakdown of all regional markets by country and split of key national industry by Formulation, Route of Administration, and Drug Type over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including industry leaders and important emerging players.

Specifically, potential risks associated with investing in global pharmaceutical manufacturing industry are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):

Abbott Laboratories

Aenova Group

Amgen

AstraZeneca

Catalent Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences

GlaxoSmithKline plc

Johnson & Johnson

Lonza Group

Lupin

Merck & Co., Inc.

Novartis AG

Novo Nordisk

Pfizer, Inc.

Roche

Sanofi SA

Takeda

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table of Contents

1 Introduction 10

1.1 Industry Definition and Research Scope 10

1.1.1 Industry Definition 10

1.1.2 Research Scope 11

1.2 Research Methodology 14

1.2.1 Overview of Industry Research Methodology 14

1.2.2 Industry Assumption 15

1.2.3 Secondary Data 15

1.2.4 Primary Data 15

1.2.5 Data Filtration and Model Design 17

1.2.6 Industry Size/Share Estimation 18

1.2.7 Research Limitations 19

1.3 Executive Summary 20

2 Industry Overview and Dynamics 23

2.1 Industry Size and Forecast 23

2.1.1 Impact of COVID-19 on World Economy 24

2.1.2 Impact of COVID-19 on the Industry 27

2.2 Major Growth Drivers 29

2.3 Industry Restraints and Challenges 32

2.4 Emerging Opportunities and Industry Trends 35

2.5 Porter’s Fiver Forces Analysis 39

3 Segmentation of Global Industry by Formulation 43

3.1 Industry Overview by Formulation 43

3.2 Tablets 45

3.3 Capsules 46

3.4 Injectable 47

3.5 Sprays 48

3.6 Suspensions 49

3.7 Powders 50

3.8 Other Formulations 51

4 Segmentation of Global Industry by Route of Administration 52

4.1 Industry Overview by Route of Administration 52

4.2 Oral Medicine 54

4.3 Topical Medicine 55

4.4 Parenteral Medicine 56

4.5 Inhalations 57

4.6 Other Routes of Administration 58

5 Segmentation of Global Industry by Age Group 59

5.1 Industry Overview by Age Group 59

5.2 Children & Adolescents 61

5.3 Adults 62

5.4 Geriatric 63

6 Segmentation of Global Industry by Therapeutic Application 64

6.1 Industry Overview by Therapeutic Application 64

6.2 Cardiovascular Diseases 66

6.3 Pain 67

6.4 Diabetes 68

6.5 Cancer 69

6.6 Respiratory Diseases 70

6.7 Neurological Diseases 71

6.8 Orthopedics 72

6.9 Other Applications 73

7 Segmentation of Global Industry by Drug Type 74

7.1 Industry Overview by Drug Type 74

7.2 Branded Prescription Drugs 76

7.3 Generic Prescription Drugs 77

7.4 OTC Drugs 78

8 Segmentation of Global Industry by Distribution Channels 79

8.1 Industry Overview by Distribution Channels 79

8.2 Retail Channels 81

8.3 Non-retail Channels 82

9 Segmentation of Global Industry by Manufacturing Facility 83

9.1 Industry Overview by Manufacturing Facility 83

9.2 In-house Facility 85

9.3 Outsourced Facility 86

10 Segmentation of Global Industry by Region 87

10.1 Geographic Industry Overview 2020-2027 87

10.2 North America Industry 2020-2027 by Country 91

10.2.1 Overview of North America Industry 91

10.2.2 U.S. 94

10.2.3 Canada 98

10.2.4 Mexico 100

10.3 European Industry 2020-2027 by Country 102

10.3.1 Overview of European Industry 102

10.3.2 UK 105

10.3.3 France 107

10.3.4 Germany 109

10.3.5 Spain 111

10.3.6 Italy 113

10.3.7 Russia 115

10.3.8 Rest of European Industry 117

10.4 Asia-Pacific Industry 2020-2027 by Country 119

10.4.1 Overview of Asia-Pacific Industry 119

10.4.2 China 122

10.4.3 Japan 124

10.4.4 India 127

10.4.5 Australia 129

10.4.6 South Korea 131

10.4.7 Rest of APAC Region 133

10.5 South America Industry 2020-2027 by Country 135

10.5.1 Argentina 138

10.5.2 Brazil 140

10.5.3 Chile 142

10.5.4 Rest of South America Industry 144

10.6 MEA Industry 2020-2027 by Country 145

10.6.1 UAE 148

10.6.2 Saudi Arabia 150

10.6.3 South Africa 152

10.6.4 Other National Markets 154

11 Competitive Landscape 155

11.1 Overview of Key Vendors 155

11.2 New Product Launch, Partnership, Investment, and M&A 158

11.3 Company Profiles 159

Abbott Laboratories 159

Aenova Group 161

Amgen 162

AstraZeneca 163

Catalent Inc. 164

Eli Lilly and Company 165

F. Hoffmann-La Roche Ltd. 166

Gilead Sciences 167

GlaxoSmithKline plc 168

Johnson & Johnson 169

Lonza Group 170

Lupin 171

Merck & Co., Inc. 172

Novartis AG 173

Novo Nordisk 174

Pfizer, Inc. 175

Roche 176

Sanofi SA 177

Takeda 178

12 Investing in Global Industry: Risk Assessment and Management 179

12.1 Risk Evaluation of Global Industry 179

12.2 Critical Success Factors (CSFs) 182

Related Reports and Products 185

Table 1. Snapshot of Global Pharmaceutical Manufacturing Industry in Balanced Perspective, 2020-2027 21

Table 2. Growth Rate of World Real GDP, 2017-2021 25

Table 3. Main Product Trends and Industry Opportunities in Global Pharmaceutical Manufacturing Industry 35

Table 4. Global Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 43

Table 5. Global Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 52

Table 6. Global Pharmaceutical Manufacturing Industry by Age Group, 2017-2027, $ bn 59

Table 7. Global Pharmaceutical Manufacturing Industry by Therapeutic Application, 2017-2027, $ bn 64

Table 8. Global Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 74

Table 9. Global Pharmaceutical Manufacturing Industry by Distribution Channels, 2017-2027, $ bn 79

Table 10. Global Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2017-2027, $ bn 83

Table 11. Global Pharmaceutical Manufacturing Industry by Region, 2017-2027, $ bn 88

Table 12. Leading National Pharmaceutical Manufacturing Industry, 2020 and 2027, $ bn 90

Table 13. North America Pharmaceutical Manufacturing Industry by Country, 2017-2027, $ bn 93

Table 14. U.S. Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 96

Table 15. U.S. Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 96

Table 16. U.S. Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 96

Table 17. Canada Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 99

Table 18. Canada Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 99

Table 19. Canada Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 99

Table 20. Mexico Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 101

Table 21. Mexico Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 101

Table 22. Mexico Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 101

Table 23. Europe Pharmaceutical Manufacturing Industry by Country, 2017-2027, $ bn 104

Table 24. UK Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 106

Table 25. UK Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 106

Table 26. UK Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 106

Table 27. France Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 108

Table 28. France Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 108

Table 29. France Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 108

Table 30. Germany Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 110

Table 31. Germany Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 110

Table 32. Germany Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 110

Table 33. Spain Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 112

Table 34. Spain Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 112

Table 35. Spain Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 112

Table 36. Italy Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 114

Table 37. Italy Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 114

Table 38. Italy Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 114

Table 39. Russia Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 116

Table 40. Russia Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 116

Table 41. Russia Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 116

Table 42. Pharmaceutical Manufacturing Industry in Rest of Europe by Country, 2017-2027, $ bn 118

Table 43. APAC Pharmaceutical Manufacturing Industry by Country, 2017-2027, $ bn 121

Table 44. China Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 123

Table 45. China Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 123

Table 46. China Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 123

Table 47. Japan Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 126

Table 48. Japan Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 126

Table 49. Japan Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 126

Table 50. India Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 128

Table 51. India Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 128

Table 52. India Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 128

Table 53. Australia Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 130

Table 54. Australia Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 130

Table 55. Australia Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 130

Table 56. South Korea Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 132

Table 57. South Korea Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 132

Table 58. South Korea Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 132

Table 59. Pharmaceutical Manufacturing Industry in Rest of APAC by Country/Region, 2017-2027, $ bn 134

Table 60. South America Pharmaceutical Manufacturing Industry by Country, 2017-2027, $ bn 137

Table 61. Argentina Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 139

Table 62. Argentina Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 139

Table 63. Argentina Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 139

Table 64. Brazil Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 141

Table 65. Brazil Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 141

Table 66. Brazil Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 141

Table 67. Chile Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 143

Table 68. Chile Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 143

Table 69. Chile Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 143

Table 70. MEA Pharmaceutical Manufacturing Industry by Country, 2017-2027, $ bn 147

Table 71. UAE Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 149

Table 72. UAE Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 149

Table 73. UAE Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 149

Table 74. Saudi Arabia Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 151

Table 75. Saudi Arabia Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 151

Table 76. Saudi Arabia Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 151

Table 77. South Africa Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 153

Table 78. South Africa Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 153

Table 79. South Africa Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 153

Table 80. Abbott Laboratories: Company Snapshot 159

Table 81. Abbott Laboratories: Business Segmentation 159

Table 82. Abbott Laboratories: Product Portfolio 160

Table 83. Abbott Laboratories: Revenue, 2017-2019, $ bn 160

Table 84. Risk Evaluation for Investing in Global Industry, 2020-2027 180

Table 85. Critical Success Factors and Key Takeaways 183

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com

Similar Reports

2020 World Blood Typing, Grouping and Infectious Disease NAT Screening Market in 68 Countries: Supplier Shares and Strategies, Volume and Sales Segment Forecasts for over 40 Tests, Technology and Instrumentation Review

This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.

The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...

  • Publish Date: March 2, 2020
  • $0
Hearing Aids Market in India 2011

Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...

  • Publish Date: March 10, 2011
  • $950
Cardiac Pacemaker Market in India 2011

The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...

  • Publish Date: July 18, 2011
  • $950